Publisher
Springer Science and Business Media LLC
Reference8 articles.
1. Peyvandi F, Kenet G, Pekrul I, Pruthi RK, Ramge P, Spannagl M (2020) Laboratory testing in hemophilia: Impact of factor and non-factor replacement therapy on coagulation assays. J Thromb Haemost 18(6):1242–1255. https://doi.org/10.1111/jth.14784
2. Mahlangu J, Oldenburg J, Paz-Priel I et al (2018) Emicizumab Prophylaxis in Patients Who Have Hemophilia A without Inhibitors. N Engl J Med 379:811–822
3. Pipe SW, Shima M, Lehle M et al (2019) Efficacy, safety, and pharmacokinetics of emicizumab prophylaxis given every 4 weeks in people with haemophilia A (HAVEN 4): a multicentre, open-label, non-randomised phase 3 study. Lancet Haematol 6:e295–e305
4. Young G, Liesner R, Chang T et al (2019) A multicenter, open-label phase 3 study of emicizumab prophylaxis in children with hemophilia A with inhibitors. Blood 134:2127–2138
5. Hemlibra European Medicines Agency (EMA) Marketing Authorisation 2018. https://www.ema.europa.eu/en/news/first-class-medicine-prevent-bleeding-haemophilia-patients-inhibitors. Zugegriffen: 20. Nov. 2021